COVID‐19 Prophylactic Effect of Bromhexine Hydrochloride
Immunity, Inflammation and Disease · 2026-04 · 14 (4)
DOI: 10.1002/iid3.70438 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunity, Inflammation and Disease, online erschienen am 20.04.2026. Verfasst von Vanyo Mitev und 4 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute of Innovative Medical Science, Medical University-Sofia, Sofia, Bulgaria. Hauptthemen laut MEDLINE: Bromhexine, COVID-19, Expectorants. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bulgarian National Science, Bulgarian National Plan for Recovery and Resilience.
Abstract (Originalsprache)
Introduction
Despite extensive efforts to identify effective treatments for COVID‐19, preventive strategies remain essential. Bromhexine hydrochloride (BRH), an over‐the‐counter mucolytic with potential TMPRSS2 inhibition, may reduce viral entry and thus serve as a prophylactic agent.
Methods
A retrospective questionnaire‐based study included 125 individuals reporting prophylactic BRH use. Demographic and clinical data were collected. COVID‐19 infection rates before and after BRH use were compared. Subgroup analyses were performed by vaccination status, prior infection, and duration of prophylaxis.
Results
Participants had a mean age of 56.5 years and a mean BMI of 25.6; 20% were vaccinated. Prior to BRH use, 62.4% reported COVID‐19 infection, compared to 11.2% after prophylaxis ( p < 0.0001). Significant reductions were observed in both vaccinated (48.1% vs. 3.7%, p = 0.002) and unvaccinated individuals (66.3% vs. 13.3%, p < 0.0001). Prior infection did not significantly influence outcomes ( p = 0.9248). Longer BRH use was associated with lower reinfection rates, decreasing from 33.3% (≤ 10 days) to 2.6% (≥ 30 days) ( p = 0.003).
Conclusions
BRH prophylaxis was associated with reduced reported COVID‐19 infection rates, independent of vaccination or prior infection, with greater benefit observed with longer use. Prospective controlled studies are required to confirm these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Institute of Innovative Medical Science, Medical University-Sofia, Sofia, Bulgaria.
- Department of Medical Chemistry and Biochemistry, Medical Faculty, Medical University-Sofia, Sofia, Bulgaria.
- Department of Propaedeutics of Internal Diseases, University Hospital Alexandrovska, Medical University-Sofia, Sofia, Bulgaria.
- Department of Bioethics, Faculty of Public Health, Medical University-Sofia, Sofia, Bulgaria.
- Department of Social Pharmacy and Pharmaco-economics, Faculty of Pharmacy, Medical University-Sofia, Sofia, Bulgaria.
ORCID-Profile: Vanyo Mitev, Tsanko Mondeshki, Ani Miteva, Konstantin Tachkov, Violeta Dimitrova
Förderung
- Bulgarian National Science
- Bulgarian National Plan for Recovery and Resilience
Zitieren
APA
Mitev, V., Mondeshki, T., Miteva, A., Tachkov, K., & Dimitrova, V. (2026). COVID‐19 Prophylactic Effect of Bromhexine Hydrochloride. Immunity, Inflammation and Disease, 14(4). https://doi.org/10.1002/iid3.70438
Vancouver
Mitev V, Mondeshki T, Miteva A, Tachkov K, Dimitrova V. COVID‐19 Prophylactic Effect of Bromhexine Hydrochloride. Immunity, Inflammation and Disease. 2026;14(4). doi:10.1002/iid3.70438
BibTeX
@article{Mitev2026,
author = {Mitev, Vanyo and Mondeshki, Tsanko and Miteva, Ani and Tachkov, Konstantin and Dimitrova, Violeta},
title = {COVID‐19 Prophylactic Effect of Bromhexine Hydrochloride},
journal = {Immunity, Inflammation and Disease},
year = {2026},
volume = {14},
number = {4},
doi = {10.1002/iid3.70438}
}
EUVIMED